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Renal hemodynamics and reduction of proteinuria by a vasodilating
beta blocker versus an ACE inhibitor. The effects of a nonselective
beta-adrenergic blocking drug with beta-2 agonist activity (dilevalol 200
mg) on proteinuria and renal hemodynamics were evaluated in a
double-blind crossover study versus an ACE inhibitor (enalapril 5 mg)
in eight patients with glomerulonephritis, moderate renal function
impairment and proteinuria >1 g/24 hr. Patients were studied after a one
week placebo phase while off all other medications, except steroids in
a few cases, and after three weeks of treatment. A 10-day placebo
washout period was included between the various drug treatments.
During each period renal heniodynamics were measured by clearance
techniques, and urinary protein excretion as well as fractional clearance
of albumin and LgG were determined. Both drugs reduced mean arterial
pressure and proteinuria to a similar extent [mean arterial pressure:
placebo 108 13 mm Hg; dilevalol 103 11 mm Hg (P < 0.05);
enalapril 103 12 mm Hg (P < 0.05); protein excretion: placebo 5.1
4.2 g/day; dilevalol 3.3 3.0 g/day (P < 0.05); enalapril 2.8 2.8 g/day(P < 0.05)]. The antiproteinuric effect was greater with enalapril than
dilevalol. Dilevalol reduced GFR [baseline inulin clearance: 73.3 38
ml/min/1.73 m2; after dilevalol: 63.3 28 ml/min/l.73 m2(P <0.05)1 and
the decrease of proteinuria correlated positively with the reduction of
GFR. Enalapril did not significantly lower the GFR (inulin clearance
during enalapril 66.8 23 mI/mm/I .73 m2) and the reduction of
proteinuna did not correlate with the lowering of the GFR. Renal blood
flow was not significantly changed either by enalapril or by dilevalol
(baseline levels of PAH clearance: 363 182 ml/min/l .73 m; after
dilevalol 382 185 ml/min/l.73 m2 and after enalapril 397 159
mI/mm/i .73 m2). Enalapril reduced the albumin excretion rate but
dilevalol did not [baseline levels: 1.5 1.0 mg/mm, dilevalol 1.3 1.0
mg/mm, enalapril 0.9 1.2 mglmmn (P < 0.05)]. In conclusion, both
drugs reduce proteinuria in patients with moderate renal function
impairment and proteinuria >1 g/24 hr and show similar effects on
hemodynamics. This reduction is supposed to be related to a reduction
of GFR and FF in case of dilevalol. Enalapril showed a more pro-
nounced reduction of proteinuria, which could be based on an increased
charge selectivity of the glomerular barrier.
Proteinuria is considered to reflect damage of the glomerular
capillary wall and glomerular hypertension in a variety of
diseases involving the kidney [1, 2]. Drugs which are able to
reduce proteinuria showed favorable effects on the progression
of renal disease [31. In the last few years a lot of work has been
done concerning the effects of angiotensin converting enzyme
inhibition with regard to this problem, especially in the rat
model [3, 4]. ACE inhibiting drugs were also investigated in
humans in conditions accompanied by proteinuria: diabetic
nephropathy [5], glomerulonephritis [6, 71, hypertension [8, 9]
and proteinuria associated with kidney transplantation [101.
Although mostly shown in retrospective studies with small
sample sizes ACE inhibiting drugs seem to be able to reduce
proteinuna and may preserve renal function in these conditions
[8, 9, 11, 12]. These beneficial effects of ACE inhibition are
considered to be based on its ability to reduce glomerular
pressure by dilating the efferent arteriole of the glomeruli [2, 4,
6, 12, 13]. As this model has been developed in animal studies,
there are doubts whether it may be applied to humans, too.
Further investigations focused on alternative explanations indi-
cated the presence of a possibly inherent impact of ACE
inhibitors on the permeability of the membrane barrier itself [1,
13—15].
Dilevalol is a new antihypertensive drug with a dual mecha-
nism of action combining vasodilatation due to selective /32-
agonisni, with nonselective /3-antagonism. In normal individu-
als and hypertensives without impairment of renal function
dilevalol had no influence on GFR, ERPF, renal blood flow or
renal vascular resistance [16]. In patients with some degree of
renal involvement ERPF was maintained whereas GFR and FF
were significantly reduced [17]. In contrast to other beta block-
ing agents renal vascular resistance was reduced by dilevalol
[17, 18]. This closely resembles effects of ACE inhibiting drugs
in patients with proteinuria and moderate renal function impair-
ment [61. The purpose of our study was to clarify whether drugs
like dilevalol could mimic ACE inhibiting actions on renal
hemodynamics and protein excretion, and to study the mecha-
nism of reduction of proteinuria in patients with proteinuria and
normal or moderately impaired renal function.
We investigated eight patients with proteinuria because of
glomerulonephritis and moderately reduced renal function in a
double-blind crossover mode. They received either dilevalol or
enalapril, a long-acting angiotensin converting enzyme inhibi-
tor, for a period of three weeks. Renal function and hemody-
namics were investigated after a one week placebo phase and
after both treatment periods.
Methods
Patients
Eight patients (3 females, 5 males) were enrolled in this
study; their mean age was 30 9 years. Informed consent was
obtained and the study was approved by the Ethics Committee.
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Table 1. Patient characteristics at entry of the study
Age MAP Creatinine
No Sex years Diagnosis mm Hg Medication mg/dl
I W 30 MGP 101 Prednisolone 2.1
2 M 23 MSPGN 133 Nifedipine 1,3
3 W 31 FSGS 96 — LI
4 M 35 MGP 92 — Li
5 M 26 MGP 102 Thiazide 1.0
6 M 25 MUP 109 Thiazide 1.5
7 W 23 MSPGN 102 Prednisolone 0.9
8 W SO FSGS 110 Nifedipine 1,0
Mean 30 106 1.3
SD 9 13 0.4
Placebo Dilevalol Enalapril
MAP mm Hg 108 13 102.5 ll 103 12U
Protein excretion glday 5.1 4.2 3.3 3.Oa 2.8 2.8a
Inulin clearance 73.3 38 63.2 28 66.8 23
mI/mm/i .73 in2
PAH clearance mI/mini 363 182 382 185 397 159
1.73 m
Filtration fraction 21 9 17.4 7 18.1 9fl
C/fl/CPA11 x 100%
Renal blood flow 485 312 500 284 502 230
mI/mm/i .73 ni2
Renal vascular resistance 22824 11234 20457 9611 19274 7702
dyn sec cm51
1.73 in2
All subjects had a normal or only mildly impaired renal func-
tion, mild arterial hypertension and proteinuria above 1 glday,
with serum protein levels not lower than 55 g/liter. Two patients
took diuretics because of mild edema for at least one year, two
patients were on nifedipine because of mild hypertension and
two others were on a long-term corticoid therapy. All drugs
except prednisolone were discontinued at the beginning of the
study. Patient characteristics are listed in Table 1. In all cases
diagnosis was proven by renal biopsy. All patients were allowed
to continue their normal diet (protein intake nearly 80 to 100
glday; sodium intake nearly 10 g/day, fluid intake nearly 2000
mI/day). The sodium and protein content of the diet was
unchanged. Except for the substances under investigation there
was no concomitant medication.
Study protocol
All patients were followed in our hypertension and nephrol-
ogy unit on an out-patient basis, To obtain stable data, blood
pressure was measured at least three times at entry of the study
(Table 1). All medication except for corticoids was withdrawn
at least two weeks before the start of the study. After a
seven-day placebo period the patients were initially investi-
gated clinically and blood samples for laboratory assays were
drawn. Patients were without medication for three weeks
except for steroids in two instances. During the following three
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weeks patients received the first drug (dilevalol 200 mg or
enalapril 5 mg) in a double-blind fashion followed by another
thorough examination. Blood pressure measurements were
obtained daily by the patients themselves for the whole study
period every morning before drug intake, and in the morning of
100
80
60 --—— 0
S
0
CD
C
4,0
a.
.4-0
C0
0
a,
Abbreviatinns are: MUP, membraneous glomerulopathy; FSGS; fo-
cal segmental sclerosis; MSPGN, mesangioproliferative glomerulone-
phritis; 512, standard deviation.
Table 2. Blood pressure, protein excretion and renal hemodynamics
during therapy with placebo, dilevalol and enalapril
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Abbreviation is MAP, mean arterial blood pressure.
a P C 0.05 compared to placebo
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Fig. 1. Correlation between reduction of proteinuria and reduction of
GFR. Symbols are: (0) dilevalol group, rs = 0.86; (j) cnalapril group,
rs = 0.48.
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Fig. 2. Correlation between reduction of proteinuria and reduction ofFE Symbols are: (0) dilevalol group, rs = 0.48; (ji) enalapril group, rs
= 0.19.
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Reduction of MAP, %
Fig. 3. Correlation between reduction of proteinuria and reduction of
MAP. Symbols are: () dilevalol group; () enalapril group.
each hospital visit. The blood pressure levels were obtained as
mean values of these measurements (Table 2). Before entering
the next treatment phase patients received placebo medication
for 10 days. Subsequently another three week period of medi-
cation ensued.
Proteinuria was assessed after a three-day collection period
starting at the fifth day of placebo intake and after 19 days of
medication. The values of proteinuria given in Tables 2 and 4
were obtained from these three-day collection periods and are
expressed as mean values SD. The differences between the
collecting days were less than 10%. During out-patient follow-
up, drugs were administered after blood pressure recordings
and blood sampling had been finished, and just before starting
the clearance measurements. Blood was also drawn for mea-
surement of hormone activities (renin, aldosterone). Addition-
ally, glomerular filtration rate (GFR) and renal blood flow
(RBF) were determined with the patients in supine position the
day before the first administration of the drug and after three
weeks of treatment. Proteinuria and creatinine clearance were
additionally assessed two weeks after ending the study when
patients were seen for regular examination. At this moment
proteinuria and creatinine clearance showed identical values in
all cases when compared to those determined at the beginning
of the study. Two weeks after withdrawing the drugs the protein
excretion was 4.7 4.35 g/day and thus reached the prestudy
level.
Methods
Blood pressure was measured with a standard mercury
sphygmomanometer. Measurements were performed in tripli-
cate after 10 minutes of rest at supine position. GFR and RPF
were measured by means of a constant infusion technique of
inulin and PAH (para-aminohippurate) after an initial loading
dose starting at 8:30 a.m. [151. C1, and CPAH parameters were
calculated as urine concentration divided by plasma concentra-
tion, multiplied by urine volume in mi/mm, and were corrected
for standard body surface area (1.73 m2). Filtration fraction
(FF) was calculated as CIfl/CPAH and was expressed as a
percentage of CPAH. RBF was calculated from CPAH by using
the peripheral venous hematocrit and assuming 74% extraction
of para-aminohippurate. Renal vascular resistance (RVR) was
calculated as mean arterial pressure/renal blood flow x 80,000.
Serum and urinary potassium, sodium, calcium, creatinine,
uric acid and albumin were measured by routine laboratory
methods. The peripheral venous hematocrit was determined via
a microhematocrit technique. Renin activities and aldosterone
were measured by radioimmunoassays (renin: Serono Diagnos-
tics; aldosterone: Diagnostic Products Corp.). Urinary protein
was determined by Biuret method in three aliquots taken over a
24-hour collection.
Determinations of the extent of disruption of the glomerular
permselective barrier have been done by measuring the urine
and plasma concentrations of albumin, IgG and inulin. Urine
albumin values were measured by ELISA technique [19].
Determination of IgG in urine and serum were done nephelo-
metrically (Behring Nephelometer Analyzer, Behring Werke,
Germany).
Fractional IgG clearance and albumin clearance were calcu-
lated as
(UIgG/PIgo)/(Uin/Pin) and (UAIb/PA(b)/(UI/P1fl)
where UJgG is urine IgG concentration in mgldl; IgG is plasma
IgG concentration in mg/dl; U is urine inulin concentration in
mg/dl; P is plasma inulin in mg/dl; UAIb is urine albumin
concentration in mgldl; and A1b is plasma albumin concentra-
tion in mg/dl.
Statistics
All data are expressed as mean standard deviation (SD).
The Wilcoxon test was used to compare percentages and
absolute values of blood pressure, renal hemodynamics, renin
values, proteinuria, plasma renin activity and fractional clear-
ances. The correlation between drug induced changes (in %) of
FF, GFR, MAP and reduction of proteinuria (in %) was
analyzed by Spearman's method with calculation of the rank
coefficient value (rs). All statistical analyses were performed
with an IBM Personal Computer Systeml2, Model 70.
Results
During dilevalol intake blood pressure decreased from a
meanoflo8±l3mmHgtoameanoflO2.5±llmmHg(P<
0.05 compared to placebo). Treatment with enalapril lowered
blood pressure to nearly the same extent (from a mean of 108
13 mm Hg to a mean of 103 12 mm Hg; P < 0.05 compared
to placebo; Table 2). Proteinuria was 5.1 4.2 g/day during
placebo, 3.3 3.0 g/day during dilevalol (P <0.05 compared to
placebo) and 2.8 2.8 glday during enalapril therapy (P < 0.05
compared to placebo; Table 2). Reduction of proteinuria with
reference to the individual percentage response data was 24.7
13.9% induced by dilevalol compared to placebo (P < 0.05), and
47 27.4% for enalapril versus placebo (P <0.05). In contrast
to enalapril, reduction of proteinuria induced by dilevalol was
associated with a reduction of GFR (rs = 0.86; Fig. 1). The
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correlation coefficient for a reduction of FF and reduction of
proteinuria was stronger for dilevalol, too (rs = 0.48 vs. rs
0.19; Figs. 2 and 3). Table 2 summarizes blood pressure data,
inulin and PAH clearances, filtration fraction, renal vascular
resistance and 24-hour protein excretion during placebo and
treatment periods. Figures 4 and 5 give the individual data
concerning renal hemodynamics and protein excretion.
GFR measured by inulin clearance was slightly reduced by
dilevalol from a mean of 73.3 38 ml/min/l.73 m2 to a mean of
63.2 28 ml/minll.73 m2 (P <0.05) and remained unaltered by
enalapril (73.3 38 mllmin/l.73 m2 vs. 66.8 23 ml/min/l.73
m2). ERPF measured by PAH clearance was slightly elevated
by both drugs (Table 2). Filtration fraction was significantly
reduced by both drtigs (dilevalol 21 9% vs. 17.4 7%, P <
0.OScomparedtoplacebo;andenalapril2l 9%vs. 18.1 9%,
P < 0.05 compared to placebo).
Renin levels were significantly increased by enalapril and
slightly decreased by dilevalol (Table 3). There was a concom-
itant but statistically not significant decline of plasma aldoste-
rone concentrations for both drugs. Other parameters did not
change significantly (Table 3).
Fractional albumin clearance was reduced significantly by
enalapril in all patients except one (Table 4, Fig. 5). Dilevalol
had no uniform effect on these values. We observed no clear-
cut change of fractional IgG clearance with both drugs (Table
4),
Discussion
Urinary protein excretion was reduced by dilevalol and
enalapril to nearly the same extent (Table 2). Renin levels were
slightly lowered by dilevalol and significantly increased in case
of enalapril treatment independent of sodium excretion. In
contrast to other beta blocking agents no reduction in renal
blood flow could be detected with dilevalol, and the renal
vascular resistance was slightly but not significantly reduced
(Table 2, Fig. 4). Interestingly, dilevalol showed the same
strong effects on renal hemodynamics as enalapril, but reduc-
tion of proteinuria seemed to be more pronounced during
enalapril (Table 2). In contrast to enalapril, reduction of pro-
teinuria induced by dilevalol was associated with a reduction of
GFR (rs 0.86) regardless of the low number of patients (Fig.
1). The correlation coefficient for reducing FF and proteinuria
was stronger for dilevalol, too (rs 0.48 vs. rs 0.19; Fig. 2).
No correlation concerning the reduction of proteinuria could be
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Fig. 4. Individual data of renal hemodynamic
changes with dilevalol and enalapril. Circles
received dilevalol first, crosses received
enalapril first.
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Table 3. Selected serum and urine values after treatment with
placebo, dilevalol and enalapril
Placebo Dilevalol Enalapril
PRA ng/ml/hr 1.5 1 1.1 0.7 5.6 3
Aldosterone pg/mi 166 99 148 70 90 58
Serum creatinine 1.6 0.7 1.6 0.7 1.6 0.7
mg/dl
Creatinine clearance 82.1 21 73.0 22 76.4 16
mi/mm/I .73 m2
Serum sodium 142 2.4 140 3.2 142 3.2
•mvai/liter
Serum potassium 4.0 0.3 4.0 0.4 4.1 0.4
•mval/liter
Serum total protein 6.1 0.8 6.2 0.6 6.2 0,6
gidi
Urinary phosphate 916 365 831 262 761 188
mg/day
Urinary sodium 189 71 165 40 169 90.5
•mval/day
Urinary potassium 68 8.5 62 17.7 64 16.2
•mval/day
Abbreviation is PRA, plasma renin activity.
a P < 0.05 compared to placebo and values under dilevalol
Fig. 5. individual data of albumin and igG
excretion during treatment with dilevalol and
enalapril. Circles received dilevalol first,
crosses received enalapril first.
Table 4. Renal protein handling in patients with glomerulonephritis
during treatment with dilevalol and enalapril
Placebo Dilevalol Enalapril
Serum albumin concentration 3.9 0.6 3.9 0.4 3.9 0.4
g/dl
Serum IgG concentration g/di 0.9 0.3 1.0 0.4 1.0 0.4
Albumin excretion rate 1.5 1.0 1.3 1.0 0.9 l.2
mg/mm
IgG excretion rate mg/mm 0.9 0.6 0.8 0.7 0.8 0.6
Fractional albumin clearance 30.6 20 33.2 22 11.7 3.8a
(x I0-)
Fractional IgG clearance 9.7 7.9 10.4 12.7 9.0 7.6
(x 1O-)
CLgG/CAIb % 45.4 48.5 46.2 54.1 74.8 59.1
a P < 0.05 compared to placebo
seen for either drug with regard to the lowering of arterial blood
pressure (Fig. 3). The observations concerning the reduction of
proteinuria by ACE inhibiting drugs independent of a reduction
of systemic blood pressure and without correlation between the
Erley et a!: Reduction of proteinuria 1301
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reduction of GFR and FF are in line with those of other authors
[6, 7]. In contrast to recently published data, proteinuria was
reduced in all patients regardless of the renin status [7].
In addition to changes of renal hemodynamics and systemic
blood pressure ACE inhibitors exert other effects which may
promote a reduction of proteinuria. There is evidence for a
change of membrane protein selectivity [12, 13, 15, 20—221. We
could not demonstrate a homogeneous alteration for either the
fractional albumin and IgG clearance, except that in all in-
stances except one the fractional albumin clearance was signif-
icantly decreased by enalapril compared to placebo and
dilevalol (Table 4, Fig. 5). Albumin clearance was considered to
reflect a selective property of the anionic constituents of the
glomerular capillary wall [20]. As shown for diabetic glomerular
disease [231, it has been proposed that loss of bather charge
selectivity provides a basis for proteinuria in glomerular disease
[15J. Data from other investigators show that dextran sieving
profiles do not change over the whole radius range during ACE
inhibition, which may be considered as an indicator for an
increased charge selectivity, although ACE inhibition lowered
the lgG-clIAlb-cl ratio in this study [21]. These data by de
Zeeuw, Heeg and de Jong [21] are in contrast to recently
published results by Remuzzi et al [241, who showed that the
transglomerular passage of large dextrans (radii 54 to 62 A), but
not of lower size (26 to 52 A), were significantly lowered by
enalapril in patients with IgA nephropathy. The same study
showed that fractional albumin clearance was also reduced by
enalapril, and this is in contrast to their above-mentioned
results, as albumin has a radius of 36 A but is negatively
charged. Data of Yoshioka et al [25, 26], obtained with two rat
models, showed that saralasin infusion leads to a partial de-
crease of excretion of large dextrans, whereas fractional clear-
ances of smaller dextrans remained unaffected. We think these
differences can be explained by patient characteristics (ne-
phrotic patients vs. patients with normal plasma albumin;
hypertensive vs. normotensive patients, differences in the un-
derlying renal disease), and probably by duration and choice of
treatment. The fact that ACE inhibition induces different
changes in protein excretion may also be a result of differences
in charge, as we only measured negatively charged proteins
with different molecular radii.
Although there was only a short second placebo phase after
the first drug administration period without another urine sam-
pling period, we assessed the same extent of reduction of
proteinuria for both drugs when given in the first period. We did
the last evaluation of proteinuria two weeks after ending the
study. In the interim patients were without medication. These
tests showed that proteinuria had returned to baseline levels at
this point in all cases (proteinuria 4.7 4.35 g/day). We cannot
exclude that after a longer time period the effects of both drugs
might differ. Unfortunately we had to discontinue our studies
on dilevalol, because there was a notification of possible
drug-related non-infectious hepatitis from Japan. Subsequently
the manufacturer withdrew dilevalol from clinical application.
Nevertheless, we consider our results interesting with regard to
work in progress on other beta blocking agents with vasodilat-
ing activities, and for other agents affecting the permselectivity
characteristics of glomerular filtration.
In conclusion, our results strongly suggest that there are
other drugs which show ACE inhibitor-like effects on renal
hemodynamics. Yet, these drugs were not able to reduce
proteinuria to the same extent as ACE inhibitors. Concerning
the mechanism of action of both drugs we found that, compared
to dilevalol, enalapril showed additional effects on the fractional
albumin excretion, indicating an increased charge selectivity of
the glomerular barrier.
Reprint requests to Christiane Erley, M.D., University of Tuebingen,
Medical Clinic, Section of Hypertension and Nephrology, Otfried-
Mueller-Str. 10, 7400 Tuebingen, Germany.
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